Mainz, Germany
BioNTech SE, founded in 2008 and headquartered in Germany, is a distinguished player in the Health Care industry, aiming to leverage the immune system for novel therapies against cancer and infectious diseases. With a workforce of approximately 6,100, BioNTech is notable for its extensive computational discovery and drug platforms, facilitating rapid development of groundbreaking biopharmaceuticals.
The company's oncology portfolio is vast, featuring individualized and off-the-shelf mRNA-based therapies, CAR T cells, bispecific immune checkpoint modulators, targeted antibodies, ADC therapeutics, and small molecules. BioNTech's expertise extends to mRNA vaccine development, where it is advancing numerous vaccine candidates addressing various infectious diseases, showcasing its versatility beyond oncology.
Although no recent investments are documented, BioNTech's comprehensive capabilities in both therapeutic and preventive domains make it a compelling candidate for investors seeking to innovate within the healthcare sector.
